Brachytherapy Seeds - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The brachytherapy seeds market size is projected to be USD 158.74 million in 2025, USD 169.25 million in 2026, and reach USD 238.40 million by 2031, growing at a CAGR of 7.09% from 2026 to 2031. This report is Segmented by Isotope Type (Iodine-125, Palladium-103, Cesium-131, Gold-198), Seed Configuration (Loose Seeds, Stranded/Linked Seeds, and More), Application (Prostate Cancer, Brain Tumors, Ocular Tumors, and More), End User (Hospitals, Cancer Centers, and More), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Brachytherapy Seeds Market Trends and Insights

Guideline-Backed Use in Localized Prostate Cancer Sustains Core Demand

National Comprehensive Cancer Network (NCCN) and American Urological Association guidelines continue to list LDR implants as definitive monotherapy for low- and favorable-intermediate-risk prostate cancer, anchoring core procedure volumes . The RTOG-9805 study showed an 8-year biochemical-failure rate of 8% with I-125 monotherapy at 145 Gy, matching radical prostatectomy outcomes with lower incontinence incidence. German reference centers such as Emmendingen report 90% cure rates across over 600 patients, highlighting the modality’s durability. Bundled German reimbursement of about EUR 19,560 (USD 21,100) per procedure sits well below typical SBRT or robotic surgery costs, preserving its attractiveness in value-based payment systems. Despite these strengths, urologists remain cautious amid SBRT’s five-fraction convenience, emphasizing the need for head-to-head long-term control data.

RSL Adoption in Breast Surgery Unlocks Adjacent Revenue Streams

Randomized controlled trials show that RSL with low-activity I-125 seeds improves patient satisfaction and eliminates same-day radiology appointments compared with wire localization . The U.S. FDA cleared IsoAid’s diagnostic-activity seeds with 180-day sterility, enabling flexible block scheduling for breast centers and reducing OR overtime. Hospitals implementing RSL report smoother workflows and reduced anxiety-related cancellations, translating into faster room turnover and higher OR throughput. Scaling RSL, however, requires MRI-compatibility checks, seed accountability logs, and radiation-safety training - barriers for community centers lacking dedicated medical physicists.

Modality Substitution Erodes LDR Volumes Despite Cost Advantages

An ASCO 2025 cohort analysis found that LDR usage fell from 3.1% to 1.0% in Medicare populations between 2009 and 2021, while SBRT grew steadily. SBRT’s five-fraction regimen frees linear-accelerator capacity and minimizes patient travel, whereas LDR implants require OR block time, anesthesia, and post-implant CT dosimetry. The NRG/RTOG-0232 trial showed no difference in freedom from progression between brachytherapy plus external beam and brachytherapy alone, weakening the rationale for combination dosing that adds toxicity.

Toxicity findings from ASCENDE-RT, including 18% late grade-3 genitourinary events, reinforce risk-averse clinician attitudes. Without randomized evidence of superior long-term biochemical control, LDR prostate volumes risk further erodes.

Other drivers and restraints analyzed in the detailed report include:

• Cs-131 Neuro-Oncology Expansion
• Workflow and Safety Gains from Preloaded Needles and Stranded Seeds
• Radioisotope Supply-Chain and Regulatory Handling Burdens Constrain Capacity

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Cs-131 revenue is projected to expand at 9.41% CAGR to 2031, the fastest among isotopes, as GT Medical’s GammaTile platform moves from early adoption to routine use in high-grade glioma surgery at more than 535 U.S. and European centers. A systematic review reported a median overall survival of 27.3 months and a median progression-free survival of 8.8 months with Cs-131 implants, reinforcing its clinical edge in aggressive neuro-oncology settings. Interim ROADS data showed superior local control versus standard care, prompting trial expansion in recurrent glioblastoma and meningioma and positioning Cs-131 as a standard-of-care adjunct for tumors requiring rapid dose delivery.

I-125 still commanded 40.02% of the 2025 brachytherapy seeds market share but is forecast to slow as SBRT substitution trims prostate case volumes despite entrenched planning-software libraries, AAPM listings, and stable reimbursement codes. A phase II trial found no significant 5-year biochemical-failure difference among I-125, Pd-103, and Cs-131, implying that operator familiarity and logistics, not efficacy, drive isotope choice once equivalence is proven.

Loose seeds still contributed 35.67% of 2025 revenues and will expand by 4.03% due to price sensitivity in community hospitals. Yet preloaded and stranded variants grow faster, propelled by safer staff dosimetry and shorter OR turnover. IsoAid supplies Mick-applicator-ready cartridges certified to ISO 13485 and the Medical Device Single Audit Program, easing tender compliance hurdles. Japanese surveys found 59 of 67 implanting centers unable to resterilize preloaded cartridges, illustrating that QA complexity stalls universal uptake. Polymer-encapsulated Pd-103 strings from CivaTech reduce needle count, curbing urethral trauma and post-void residuals; five-year data showed negligible late toxicity, supporting premium positioning.

Hospitals performing more than 200 prostate cases annually increasingly shift to stranded or preloaded systems, citing a 15-minute median reduction in theater time and a 22% cut in radiation technologist exposure. Despite higher acquisition costs, these formats shrink revision rates, indirectly safeguarding reimbursement margins tied to bundled case payments.

Complete Report Scope:

• By Isotope Type
  • Iodine-125 (I-125)
  • Palladium-103 (Pd-103)
  • Cesium-131 (Cs-131)
  • Gold-198 (Au-198)
• By Seed Configuration
  • Loose Seeds
  • Stranded/Linked Seeds
  • Preloaded Needles & Cartridges
• By Application
  • Prostate Cancer
  • Brain Tumors
  • Ocular Tumors
  • Head & Neck, Lung, Liver and Other Indications
• By End User
  • Hospitals
  • Cancer Centers/Specialty Clinics
  • Academic and Research Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of APAC
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of MEA
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 45.35% of 2025 spend, underpinned by 20-plus years of established treatment-planning software, ADCL calibration labs, and mature reimbursement. Yet ASCO data show LDR share shrinking below 1% of prostate treatments as SBRT surges, illustrating a secular decline in risk despite entrenched installed bases. Europe trails in share but hosts high-volume German, Spanish, and Italian reference sites that offer centralized seed-implant services to neighboring countries, partially offsetting mixed reimbursement climates in the United Kingdom and France.

Asia-Pacific is the fastest-growing region at a projected 9.12% CAGR to 2031. Japan legalized permanent I-125 implants only in 2003; over 70 institutes now perform the procedure, but only 18% conduct dosimetric assays, suggesting latent QA investment demand. China’s National Medical Products Administration fast-tracked domestic Cs-131 and I-125 seed registrations, while local firms use micro-beam plasma welding and silver-rod halogenation to minimize leakage and shorten two-week batch cycles - advantages that compress landed costs by up to 30% versus imports. India, South Korea, and Australia are experiencing mid-single-digit growth, constrained by radiotherapy workforce density. Latin America and Middle East-Africa remain nascent but could benefit from turnkey brachytherapy suites bundled with isotope supply contracts once regional regulatory harmonization advances.

List of Companies Covered in this Report:

• BARC
• Beckton Dickinson
• Best Medical International
• BXTA
• CivaTech Oncology
• Eckert & Ziegler
• Eye Physics
• GT Medical Technologies
• IsoAid LLC
• Ningbo Junan Pharmaceutical Technology
• Perspective Therapeutics
• Shanghai GMS Pharmaceutical
• Theragenics
• Tianjin Said Biopharmaceutical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support